Trough (pre dose) specimen required
Managing inflammatory diseases with biological medicines such as Ustekinumab is challenging. Patients may respond well to treatment initially, only to encounter loss of response further ahead in their treatment pathway. Others may not respond to treatment at all. One approach to potentially improve outcomes for patients on Ustekinumab is to measure trough drug levels. However, drug level testing will only be useful if it actually creates positive outcomes for patients. The challenge lies in optimising when this analysis takes place and how best to interpret the data in making clinical decisions that benefit patients. It is widely accepted that undetectable drug level is associated with poor clinical outcomes. Based on available data, the suggested therapeutic range for Ustekinumab during maintenance is 1.1 to 1.4 mg/L*.
*Please note: This data was generated using a different methodology and the therapeutic range may be slightly different on our assay. We are in the process of undertaking a method comparison to understand these potential differences.
*Adedokun OJ et al. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn’s Disease. Gastroenterology 2018;154:1660–1671
Can be added on to an existing request
We welcome referrals for Ustekinumab monitoring. If you are a new requestor please complete the following form: New requestor form.
We now also have the option to use NPEx for referral requesting.
Our Quality Statement for referred work can be found here : Quality statement May 2019 (134 downloads)Specimen Labelling Procedure